{"url_path":"/sec/phge/10-q/2026/item-1a","section_key":"item-1a","section_title":"Item 1A Risk Factors**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/1739174/0001213900-26-059587-index.html","accession_number":"0001213900-26-059587","cik":"0001739174","ticker":"PHGE","issuer_name":"BiomX Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1739174/0001213900-26-059587-index.html","primary_entity_key":"0001739174","primary_entity_name":"BiomX Inc."},"word_count":165,"has_tables":true,"body_markdown":"** **\n\n**Item 1A. Risk Factors**\n\n** **\n\nIn addition to the other information\nset forth in this Quarterly Report, including in the section captioned “Cautionary Statement Regarding Forward-Looking Information”\nabove, you should carefully consider the risk factors discussed in Part I, Item 1A “Risk Factors” of the 2025 10-K, as updated\nand supplemented by the risk factors relating to the Company’s strategic transition and new business focus set forth in the May 5 8-K.\nThese risks could materially affect the Company’s business, financial condition, results of operations, cash flows, and the trading price\nof the Common Stock.\n\n \n\nOther than as set forth in\nthe May 5 8-K and as supplemented by the disclosures contained elsewhere in this Quarterly Report (including with respect to the Company’s\nNYSE American continued listing matters, the Company’s going-concern conclusion, the integration of the recently acquired operating subsidiaries,\nand the matters described in “Liquidity and Capital Resources” above), there have been no material changes to the risk factors\nset forth in the 2025 10-K."}